Tofacitinib, which inhibit JAK1, JAK2, and JAK3, and baricitinib and ruxolitinib, both acting against JAK1 and JAK2 are currently under investigation for COVID-19 (Kalil et al., 2021). This evidence concerns the gene JAK2 and COVID-19.